Novel therapeutic approaches for uveitis and retinitis

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue 3, 2001, Pages 248-254

  Thilek Kumar, M ^a   Pandit, J K ^a   Balasubramaniam, J ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 O HEXADECYL PROPANEDIOL 3 PHOSPHO GANCICLOVIR; ALGINIC ACID; CYCLOSPORIN; CYCLOSPORIN A; FOSCARNET; GANCICLOVIR; GANCICLOVIR DERIVATIVE; INDOMETACIN; LIPOSOME; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMER; STEROID; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ARTICLE; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EPIGASTRIC PAIN; GINGIVITIS; HUMAN; HYPERESTHESIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PARESTHESIA; RABBIT; RAT; REINFECTION; RETINITIS; RETINOPATHY; SEPSIS; SUSTAINED RELEASE FORMULATION; UVEITIS; VIRUS REACTIVATION;

ANIMALS; CYTOMEGALOVIRUS; DRUG DELIVERY SYSTEMS; HUMANS; RETINITIS; UVEITIS;

EID: 0035734625     PISSN: 14821826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Polymeric Systems for ophthalmic drug delivery
2. Ocular drug delivery- conventional ocular formulations
3. Importance of the noncorneal absorption roue in topical ophthalmic drug delivery
4. Nasal and conjunctival contributions to the systemic absorption of topical timolol in pigmented rabbits: Implications in the design of strategies to maximize the ratio of ocular to systemic absorption
5. Corneal penetration behaviour of β-blocking agents I: Physico-chemical factors
6. Mechanisms of corneal drug penetration II: Ultrastructural analysis of potential pathways for drug movement
7. The effect of poly ethylene glycol molecular weight on corneal transport and the related influence of penetration enhancers
8. Paracellular permeability of corneal and conjunctival epithelia
9. The transport barrier of epithelia: A comparative study on membrane permeability and charge selectivity in the rabbit
10. The effect of drug charge type and charge density on corneal transport
11. Vehicle effects on ocular drug bioavailability II. Evaluation of pilocarpine
12. Ocular pharmacology of sulfonamides: The cornea as barrier and depot
13. pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors
14. L'aspect clinique et immunitaire des iridocyclites rhumatismates
15. Deletion of circulating antigen-antibody complexes by their inhibitory effect on the agglutination of Ig G-coated particles by rheumatoid factor or clq
16. Behcet's disease
17. Pseudophakic cystoid maculopathy: A study of 50 cases
18. Ocular inflammation and anti-inflammatory drugs
19. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter
20. Cyclosporine A and dexamathasone suppress T-cell responses by selectively acting at distinct sites of the triggering process
21. Ocular penetration of cyclosporine A in the rat eye
22. Comparison of the efficacy of unilateral, bilateral and oral cyclosporine in experimental immunogenic uveitis in rabbits
23. The use of cyclosporine in ocular inflammatory disorders
24. Transport functions of the blood-ocular and blood-brain barriers, and the micro environment of neuronal and non-neuronal tissues
25. Relationship between the ocular and systemic disposition of flurbiprofen: The effect of altered protein dynamics at steady state
26. Acquired immune deficiency syndrome. Ocular manifestations
27. Acquired immuno deficiency syndrome. Ophthalmic manifestations in ambulatory patients
28. Ophthalmic involvement in AIDS
29. Ophthalmologic findings in AIDS
30. A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome
31. Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease
32. Infections of the retina in AIDS
33. Cytomegalovirus retinitis and response to therapy with ganciclovir
34. Mortality in patients with acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies on ocular complications of AIDS research group
35. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS
36. Intravitreal ganciclovir in CMV retinitis: Case report
37. Local cyclosporine therapy for experimental autoimmune uveitis in rats
38. Evaluation of a delivery system providing long term release of cyclosporine
39. Retinal toxicity of intravitreal cyclosporine
40. Intravitreal ganciclovir concentration after intravenous administration in AIDS patient with CMV retinitis: Implication for therapy
41. Treatment of CMV retinitis with intravitreal injections of liposome encapsulated ganciclovir in a patient with AIDS
42. Intravitreal delivery of ganciclovir in rabbits by trans-scleral iontophoresis
43. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation
44. Cyclosporine-A: Models for the mechanism of action
45. Ocular penetration of cyclosporine-A, III: The human eye
46. In vitro and in vivo characterization of scleral implants of indomethacin
47. Intravitreal Ganciclovir Pharmacokinetics in rabbits and man
48. Intravitreal sustained-release ganciclovir
49. Sustained release ganciclovir therapy for treatment of CMV retinitis
50. Treatment of Cytomegalovirus Retinitis with an Intraocular Sustained-release ganciclovir implant
51. Replacing ganciclovir implants